Last reviewed 2026-05-31 · How we verify

AGN-210669 ophthalmic solution, 0.05%

Allergan · Phase 2 active Small molecule Under review

AGN-210669 ophthalmic solution, 0.05% is a Corticosteroid Small molecule drug developed by Allergan. It is currently in Phase 2 development for Treatment of non-infectious uveitis affecting the posterior segment of the eye.

AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.

AGN-210669 ophthalmic solution is a small molecule used to treat conditions such as open-angle glaucoma and ocular hypertension. It is compared to bimatoprost ophthalmic solution in clinical trials for its safety and efficacy.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AGN-210669 ophthalmic solution, 0.05%
Sponsor	Allergan
Drug class	Corticosteroid
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	Phase 2

Mechanism of action

Corticosteroids like AGN-210669 work by inhibiting the production of inflammatory mediators, thereby reducing swelling and pain in the eye. This is achieved through the suppression of phospholipase A2, an enzyme involved in the production of prostaglandins and leukotrienes, which are key players in the inflammatory response.

Approved indications

Treatment of non-infectious uveitis affecting the posterior segment of the eye

Common side effects

Increased intraocular pressure

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AGN-210669 ophthalmic solution, 0.05% CI brief — competitive landscape report
AGN-210669 ophthalmic solution, 0.05% updates RSS · CI watch RSS
Allergan portfolio CI

Frequently asked questions about AGN-210669 ophthalmic solution, 0.05%

What is AGN-210669 ophthalmic solution, 0.05%?

AGN-210669 ophthalmic solution, 0.05% is a Corticosteroid drug developed by Allergan, indicated for Treatment of non-infectious uveitis affecting the posterior segment of the eye.

How does AGN-210669 ophthalmic solution, 0.05% work?

AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.

What is AGN-210669 ophthalmic solution, 0.05% used for?

AGN-210669 ophthalmic solution, 0.05% is indicated for Treatment of non-infectious uveitis affecting the posterior segment of the eye.

Who makes AGN-210669 ophthalmic solution, 0.05%?

AGN-210669 ophthalmic solution, 0.05% is developed by Allergan (see full Allergan pipeline at /company/allergan).

What drug class is AGN-210669 ophthalmic solution, 0.05% in?

AGN-210669 ophthalmic solution, 0.05% belongs to the Corticosteroid class. See all Corticosteroid drugs at /class/corticosteroid.

What development phase is AGN-210669 ophthalmic solution, 0.05% in?

AGN-210669 ophthalmic solution, 0.05% is in Phase 2.

What are the side effects of AGN-210669 ophthalmic solution, 0.05%?

Common side effects of AGN-210669 ophthalmic solution, 0.05% include Increased intraocular pressure.

Drug class: All Corticosteroid drugs
Manufacturer: Allergan — full pipeline
Therapeutic area: All drugs in Ophthalmology
Indication: Drugs for Treatment of non-infectious uveitis affecting the posterior segment of the eye

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing